MedPath

China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)

Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Registration Number
NCT05221580
Lead Sponsor
Novo Nordisk A/S
Brief Summary

The purpose of this study is to collect information on how Ryzodeg® works in real-world patients.

Participants will get Ryzodeg® as prescribed to by their doctor. The study will last for about 5-8 months. Participants will be asked questions about their health and their diabetes treatment as part of their normal doctor's appointment

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
887
Inclusion Criteria
  1. Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
  2. The decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on the approved Ryzodeg® label in China and independently from the decision to include the patient in this study.
  3. Male or female, age above or equal to 18 years at the time of signing informed consent.
  4. Diagnosed with T2DM and treated with any anti-hyperglycaemic medication(s) other than Ryzodeg® for at least 20 weeks prior to Treatment Initiation Visit (Visit 1).
  5. Available and documented Glycosylated haemoglobin (HbA1c) value below or equal to 12 weeks prior to Informed Consent and Treatment Initiation Visit (Visit 1).
Exclusion Criteria
  1. Previous participation in this study. Participation is defined as having given informed consent in this study.
  2. Treatment with any investigational drug within 30 days prior to enrolment into the study.
  3. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
  4. Known or suspected hypersensitivity to the active substance or to any of the excipients as specified in the approved Ryzodeg® label in China.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Real-world adult population of Chinese patients with T2DMRyzodeg®Ryzodec as per local clinical practise
Primary Outcome Measures
NameTimeMethod
Change in Glycosylated Haemoglobin (HbA1c)From baseline (week 0) to end of study (week 20 to 32)

Percentage point

Secondary Outcome Measures
NameTimeMethod
Change in Fasting Plasma Glucose (FPG)From baseline (week 0) to end of study (week 20 to 32)

mmol/L

Change in insulin dose (total, basal, prandial)From baseline (week 0) to end of study (week 20 to 32)

units/day

Patient preference compared to previous treatmentAt baseline and end of study (week 20 to 32)

Percentage of patients who prefer to continue treatment with Ryzodeg® over previous treatment. Assessed by questionnaire

Change in body weightFrom baseline (week 0) to end of study (week 20 to 32)

Kg

HbA1c less than 7 percent (Yes/No)At the end of study (week 20 to 32)

Percentage of patients

HbA1c less than 7 percent without any hypoglycaemic episodes during 4 weeks prior to end of study (Yes/No)At the end of study (week 20 to 32) Hypoglycaemic episodes occurring within 4 weeks prior to end of study (week 20 to 32).

Percentage of patients

Treatment satisfaction questionnaire (Diabetes Treatment Satisfaction Questionnaire (DTSQ))At baseline and end of study (week 20 to 32)

Score based on items 1, 4, 5, 6, 7 and 8. Range 0-36, where higher score means greater satisfaction (better outcome)

Trial Locations

Locations (50)

NIS-The First People's Hospital of Yulin City

🇨🇳

Yulin, Guangxi, China

NIS-Third Affiliated Hospital of Jinzhou Medical University

🇨🇳

Jinzhou, Liaoning, China

NIS-Zhejiang Provincial People's Hospital

🇨🇳

Hangzhou, Zhejiang, China

NIS-The Third People's Hospital of Dalian

🇨🇳

Dalian, Liaoning, China

NIS-The Second People's Hospital of Hefei

🇨🇳

Hefei, Anhui, China

NIS-The people's hospital of JiangMen

🇨🇳

Jiangmen, Guangdong, China

NIS-Changshu Second People's Hospital

🇨🇳

Changshu, Jiangsu, China

NIS-Huai'an First People's Hospital

🇨🇳

Huai'an, Jiangsu, China

NIS-De Hong Zhou People's Hospital

🇨🇳

Mang, Yunnan, China

NIS-Beijing Hospital

🇨🇳

Beijing, Beijing, China

NIS-Beijing Friendship Hospital, Capital Medical University

🇨🇳

Beijing, Beijing, China

NIS-People's Hospital of Chongqing Banan District

🇨🇳

Chongqing, Chongqing, China

NIS-Gansu Provincial People's Hospital

🇨🇳

Lanzhou, Gansu, China

NIS-2nd Affiliated Hospital of Shantou University Medical

🇨🇳

Shantou, Guangdong, China

NIS-Shenzhen Longgang District People's Hospital

🇨🇳

Shenzhen, Guangdong, China

NIS-Yangjiang People's Hospital

🇨🇳

Yangjiang, Guangdong, China

NIS-Hainan Provincial Hospital of TCM

🇨🇳

Haikou, Hainan, China

NIS-Cangzhou Hosp of Integrated Traditional Chinese Medicine

🇨🇳

Cangzhou, Hebei, China

NIS-The First Hospital of Handan

🇨🇳

Handan, Hebei, China

NIS-The First Hospital of Qinhuangdao

🇨🇳

Qinhuangdao, Hebei, China

NIS-Puai Hospital of Wuhan

🇨🇳

Wuhan, Hubei, China

NIS-Zhengzhou University - The Second Affiliated Hospital

🇨🇳

Zhengzhou, Henan, China

NIS-Heilongjiang Provincial Hospital

🇨🇳

Harbin, Heilongjiang, China

NIS-Shiyan City People's Hospital

🇨🇳

Shiyan, Hubei, China

NIS-The Sceond Hospital of Chifeng

🇨🇳

Chifeng, Inner Mongolia Autonomous Region, China

NIS-Inner Mongolia University for Nationalities - Affiliated

🇨🇳

Tongliao, Inner Mongolia Autonomous Region, China

NIS-The Third Xiangya Hospital of Central South University

🇨🇳

Changsha, Hunan, China

NIS-Nantong University - Affiliated Hospital

🇨🇳

Nantong, Jiangsu, China

NIS-Nanjing Jiangning Hospital

🇨🇳

Nanjing, Jiangsu, China

NIS-Jiangsu Province Officeial Hospital

🇨🇳

Nanjing, Jiangsu, China

NIS-Yixing City People's Hospital

🇨🇳

Yixing, Jiangsu, China

NIS-Affiliated Hospital of Jilin Medical College

🇨🇳

Jilin, Jilin, China

NIS-Songyuan Jilin Oilfield Hospital

🇨🇳

Songyuan, Jilin, China

NIS-Huludao Central Hospital

🇨🇳

Huludao, Liaoning, China

NIS-The Fourth Hospital of China Medical University

🇨🇳

Shenyang, Liaoning, China

NIS- Qinghai Red Cross Hospital

🇨🇳

Xining, Qinghai, China

NIS-Hanzhong Central Hospital

🇨🇳

Hanzhong, Shaanxi, China

NIS-Xi'an No.3 Hospital

🇨🇳

Xi'an, Shaanxi, China

NIS-Binzhou Medical University-Yantai Affiliated Hospital

🇨🇳

Yantai, Shandong, China

NIS-Central hospital of zibo

🇨🇳

Zhibo, Shandong, China

NIS-Shanghai Shidong Hospital

🇨🇳

Shanghai, Shanghai, China

NIS-Shanxi Bethune Hospital

🇨🇳

Taiyuan, Shaanxi, China

NIS-Weifang Medical University - Affiliated Hospital

🇨🇳

Weifang, Shandong, China

NIS-The People's Hospital of Ningxia Hui Autonomous Region

🇨🇳

Yinchuan, Ningxia Hui Autonomous Region, China

NIS-Affiliated Hospital of North Sichuan Medical College

🇨🇳

Nanchong, Sichuan, China

NIS-Metabolic Diseases Hosp&Tianjin Institute of Endocrinolo

🇨🇳

Tianjin, Tianjin, China

NIS-Shanghai Shuguang Hospital

🇨🇳

Shanghai, Shanghai, China

NIS-Tianjin First Center Hospital

🇨🇳

Tianjin, Tianjin, China

NIS-The First People's Hospital of Qujing

🇨🇳

Qujing, Yunnan, China

NIS-Shaoxing Central Hospital

🇨🇳

Shaoxing, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath